147 related articles for article (PubMed ID: 15251983)
1. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant.
Syrjala KL; Dikmen S; Langer SL; Roth-Roemer S; Abrams JR
Blood; 2004 Nov; 104(10):3386-92. PubMed ID: 15251983
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.
Sharafeldin N; Bosworth A; Patel SK; Chen Y; Morse E; Mather M; Sun C; Francisco L; Forman SJ; Wong FL; Bhatia S
J Clin Oncol; 2018 Feb; 36(5):463-475. PubMed ID: 29252122
[TBL] [Abstract][Full Text] [Related]
3. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years.
Syrjala KL; Artherholt SB; Kurland BF; Langer SL; Roth-Roemer S; Elrod JB; Dikmen S
J Clin Oncol; 2011 Jun; 29(17):2397-404. PubMed ID: 21537032
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
7. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
9. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study.
Scherwath A; Schirmer L; Kruse M; Ernst G; Eder M; Dinkel A; Kunze S; Balck F; Bornhäuser M; Ehninger G; Dolan K; Gramatzki M; Kolb HJ; Heußner P; Wilhelm H; Beelen DW; Schulz-Kindermann F; Zander AR; Koch U; Mehnert A
Psychooncology; 2013 Jul; 22(7):1509-16. PubMed ID: 22945857
[TBL] [Abstract][Full Text] [Related]
10. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.
Syrjala KL; Langer SL; Abrams JR; Storer B; Sanders JE; Flowers ME; Martin PJ
JAMA; 2004 May; 291(19):2335-43. PubMed ID: 15150205
[TBL] [Abstract][Full Text] [Related]
11. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns.
Wong FL; Francisco L; Togawa K; Bosworth A; Gonzales M; Hanby C; Sabado M; Grant M; Forman SJ; Bhatia S
Blood; 2010 Mar; 115(12):2508-19. PubMed ID: 20089962
[TBL] [Abstract][Full Text] [Related]
12. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
14. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation.
Jim HS; Small B; Hartman S; Franzen J; Millay S; Phillips K; Jacobsen PB; Booth-Jones M; Pidala J
Cancer; 2012 Jul; 118(13):3407-16. PubMed ID: 22139882
[TBL] [Abstract][Full Text] [Related]
16. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
18. Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant.
Basinski JR; Alfano CM; Katon WJ; Syrjala KL; Fann JR
Biol Blood Marrow Transplant; 2010 Jun; 16(6):824-31. PubMed ID: 20100587
[TBL] [Abstract][Full Text] [Related]
19. Worsening cognitive performance is associated with increases in systemic inflammation following hematopoietic cell transplantation.
Hoogland AI; Nelson AM; Gonzalez BD; Small BJ; Breen EC; Sutton SK; Syrjala KL; Bower JE; Pidala J; Booth-Jones M; Jacobsen PB; Jim HSL
Brain Behav Immun; 2019 Aug; 80():308-314. PubMed ID: 30953767
[TBL] [Abstract][Full Text] [Related]
20. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
